Menu
Search
|

Menu

Close
X

Uniqure NV QURE.OQ (NASDAQ Stock Exchange Global Select Market)

61.95 USD
-1.48 (-2.33%)
As of 4:00 PM EDT
Previous Close 63.43
Open 63.50
Volume 150,469
3m Avg Volume 144,671
Today’s High 65.45
Today’s Low 61.20
52 Week High 69.60
52 Week Low 21.60
Shares Outstanding (mil) 37.63
Market Capitalization (mil) 2,386.64
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.55 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY18
8
FY17
12
FY16
23
EPS (USD)
FY18
-1.469
FY17
-2.637
FY16
-2.649
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.10
Price to Sales (TTM)
vs sector
211.51
8.84
Price to Book (MRQ)
vs sector
13.19
4.60
Price to Cash Flow (TTM)
vs sector
--
40.07
Total Debt to Equity (MRQ)
vs sector
19.75
17.66
LT Debt to Equity (MRQ)
vs sector
19.75
13.97
Return on Investment (TTM)
vs sector
-37.49
12.12
Return on Equity (TTM)
vs sector
-61.94
13.24

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Paasheuvelweg 25a
AMSTERDAM     1105 BP

Phone: +3120.2406000

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company’s product candidates within the Core Program include AMT-061 for Hemophilia B, AMT-130 for Huntington's disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.

SPONSORED STORIES